Albumin-based drug delivery: harnessing nature to cure disease

  • Maja Thim Larsen Interdisciplinary Nanoscience Center (iNANO), Department of Molecular Biology and Genetics, University of Aarhus, Aarhus, Denmark
  • Matthias Kuhlmann Interdisciplinary Nanoscience Center (iNANO), Department of Molecular Biology and Genetics, University of Aarhus, Aarhus, Denmark
  • Michael Lykke Hvam Interdisciplinary Nanoscience Center (iNANO), Department of Molecular Biology and Genetics, University of Aarhus, Aarhus, Denmark
  • Kenneth A. Howard Interdisciplinary Nanoscience Center (iNANO), Department of Molecular Biology and Genetics, University of Aarhus, Aarhus, Denmark

Abstract

The effectiveness of a drug is dependent on accumulation at the site of action at therapeutic levels, however, challenges such as rapid renal clearance, degradation or non-specific accumulation requires drug delivery enabling technologies. Albumin is a natural transport protein with multiple ligand binding sites, cellular receptor engagement, and a long circulatory half-life due to interaction with the recycling neonatal Fc receptor. Exploitation of these properties promotes albumin as an attractive candidate for half-life extension and targeted intracellular delivery of drugs attached by covalent conjugation, genetic fusions, association or ligand-mediated association. This review will give an overview of albumin-based products with focus on the natural biological properties and molecular interactions that can be harnessed for the design of a next-generation drug delivery platform.

Published
2016-02-27
How to Cite
LARSEN, Maja Thim et al. Albumin-based drug delivery: harnessing nature to cure disease. Molecular and Cellular Therapies, [S.l.], v. 4, n. 1, feb. 2016. ISSN 2052-8426. Available at: <http://molcelltherapies.com/article/view/25>. Date accessed: 23 aug. 2017. doi: https://doi.org/10.1186/s40591-016-0048-8.